Background: ICIs can overcome immune-suppression and activate effective immune responses against cancer cells. Therapy with ICIs have led to a clinically-meaningful extension in overall survival across several solid tumors, being endowed with long term disease control-rate in a part of responding patients (pts). However, an acceleration of the tumor growth rate (TGR) during ICI, defined as hyperprogressive disease (HPD), has been reported in 9-29% of pts. Mechanisms underlying HPD are unknown, yet murine double minute 2 (MDM2) family amplification was found in some of these pts. Methods: We retrospectively identified a series of 334 pts with miscellaneous advanced solid tumors treated with anti-PD1/PD-L1-containing ICI (mono or combo therapy) at our Institution. Inclusion criteria included imaging assessment at 3 timepoints: during reference period (from 3 months to 2 weeks before ICI baseline scan), before ICI therapy start (baseline scan, performed within 28 days) and during ICI treatment. Patients were considered HPD if they showed progressive disease (PD) by RECIST 1.1 at first radiological evaluation and a 2-fold increase of the TGR during ICI therapy compared to reference period. FISH analysis to evaluate MDM2 family genes amplification was performed in HPD cases whose paraffin embedded tumor material was available.
Background: Immune checkpoint inhibitor (CPI) induced acute liver injury (ALI) is a frequently encountered toxicity occurring in up to 30% patients (pts). There is a lack of systemic evaluation of CPI induced ALI pathogenesis, clinical evolution and outcome of patients (pts). Methods: Retrospective analysis was performed on pts with CPI induced ALI presenting to 6 UK oncology centres between 2013-17. Indices of ALI, therapy complications and outcome were recorded. ALI grading was based on Common Terminology Criteria for Adverse Events. Results: 65% (36/57) pts received ipilimumabþnivolumab (N) or pembrolizumab (P) (combo group) and 35% (21/57) P or N alone (mono group). Median therapy duration to ALI onset was 96 days in the mono and 22 days in the combo group. At presentation, all pts had acute elevations in transaminases (ALT, median 325U/L [range , ALP 111U/L ). Immunogolulins and autoantibodies were normal. One pt developed acute synthetic dysfunction without encephalopathy (Bilirubin 64umol/L, INR 1.5). 79% received steriods (mean dose 1.3mg/kg); 34% MMF. Steroid refractory ALI was treated with anti-thymocyte globulin (ATG) in 4 pts. Pathological findings (n ¼ 6 liver biopsies) revealed lobular hepatitis and myelo-lymphoid cell infiltrate/ aggregates (CD3þ,CD8þ,CD68þ). Pts with severe, refractory (G4) ALI had significant reductions in circulating lymphocytes/monocytes. 63% (n ¼ 35) had a temporal association between recent infection and ALI. 15% (n ¼ 8) also received anti-TNF-a therapy for colitis. This was not associated with more severe ALI, and ALI resolved in all cases. 21% (n ¼ 11) developed bacterial infections. Fungal sepsis (aspergillus) occurred in all ATG (n ¼ 4) treated patients. Overall no deaths were due to liver failure. 14 pts died with 13 due to disease progression and 1 due to immunotherapy related neuropathy. All deaths due to progressive disease were in pts whose ALI peaked at G3-4. Acturial median survival was significantly lower in G3-4 (14.5 months) vs G1-2 (25 months) liver injury. Conclusions: Our data report on the largest cohort of CPI induced ALI identifying disease evolution, markers of disease severity and strong correlation with increased morbidity and mortality. Background: 2L tx for SCLC is heavily dependent on 1L platinum (PT) response. NCCN guidelines recommend PT retreatment if recurrence is > 3-6 months post 1L PT; while alternative options should be considered for rapid relapse (topotecan [TOP] in 2L PT-resistant). In 2016, nivolumab (NIVO) þ/-ipilimumab (IPI), were added to 2L NCCN guidelines. This study evaluates 2L SCLC patterns of care and outcomes and attempts to contextualize CheckMate 032 data by creating a matched real-world comparator. Methods: Adult SCLC pts receiving systemic tx from the Flatiron Health database were selected (01Jan2011-30Sep2017). Index date was SCLC diagnosis (dx). Pts were included if: not on clinical trial; no secondary malignancy within 3 years (y); no IO use; and 2 months (mo) of medical data on/after dx. PT sensitivity was based on a 90 day gap. Median, 1-y and 2-y overall survival (OS) by Kaplan-Meier was calculated from 2L initiation to death. Median duration of therapy (mDoT) was assessed. A matched 2L cohort was constructed using CheckMate 032 Inclusion/Exclusion criteria (I/E). Results: 2,056 pts initiated 1L tx (full cohort), of which 628 pts went on to 2L; 42% received TOP and 58% other txs. Within 2L, mean age was 65y; 69% were white, 51% were female, 98% had a smoking history and 95% were treated in the community. Of 2L pts, 68% had extensive and 27% had limited disease at dx. 372 were PT-sensitive and 231 pts were PT-resistant. Upon matching for CheckMate 032 I/E, 903 pts were identified of whom 254 initiated 2L. For the full and matched cohorts respectively, 2L mDoT for TOP was 2.0 mo (SD ¼ 2.5) and 2.2 mo (SD ¼ 2.7) and for other tx was 2.6 mo (SD ¼ 2.2) and 2.8 mo (2.4). Median, 1-y and 2-y OS results for the full/ matched cohorts and CheckMate 032 are shown (Table) . Background: In clinical practice, the sequential use of shifting from a programmed cell death 1 (PD-1) inhibitor to its ligand 1 (PD-L1) inhibitors in consideration of ineffectiveness or toxicity is becoming more common due to prolonged survival. We report a patient in whom fatal myocarditis developed after sequential use of PD-1 and PD-L1 inhibitors. To validate this finding, a syngeneic tumor-bearing mice model was used. Methods: A 61-year-old woman with metastatic lung adenocarcinoma, who had received 5 doses of nivolumab (3 mg/kg) and then 1 dose of atezolimumab (1200 mg), complained of chest tightness and dyspnea 4 weeks later. The workup revealed sinus tachycardia, a normal Troponin I level (< 0.01 ng/mL), an elevated creatine kinasemyocardial band (CK-MB) level (10 ng/mL), and an elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) level (2960 ng/mL). Serial echocardiograms revealed left ventricular ejection fractions declining from 66.3 to 59.2 %. Under a diagnosis of myocarditis, she was treated with intravenous methylprednisolone at 5 mg/kg/day and oral mycophenolate mofetil at 1000 mg/day. The progressive clinical deterioration was noted with serial elevation of Troponin I, CK-MB and NT-proBNP levels up to 1.3, 24 and 15738 ng/mL, respectively. Cardiac arrest was noted later. The Balb/c mice bearing lung metastasis of CT26 colon cancer cells were treated with PD-1 and PD-L1 inhibitors for pathological and immuohistochemical studies. Results: The pathology shows that the combination of anti-PD-1 and anti-PD-L1, either sequentially or simultaneously administered, caused myocarditis lesions with myocyte injury and patchy mononuclear infiltrates in the myocardium in all combination group mice (n ¼ 3 for each). The myocarditis lesions were not seen in mice treated with anti-PD-1 or anti-PD-L1 alone. Marked expression of PD-L1 in infiltrating lymphocytes and expression of PD-1 in myocytes was noted only in mice with combination blockade, implying a possible role for pathogenesis of myocarditis. Conclusions: The combinatory use of PD-1 and PD-L1 blockade, either sequentially or concurrently, may cause fulminant cardiotoxicity, and such usage should be cautious. Legal entity responsible for the study: Mackay Memorial Hospital, Taipei, Taiwan. Funding: Mackay Memorial Hospital, Taipei, Taiwan. Disclosure: All authors have declared no conflicts of interest.
1216P Impact of anti-infectious and corticosteroids on immunotherapy:
Nivolumab and pembrolizumab follow-up in a French study of these patients received an antibiotic, 17% a corticoid and 2% an antifungal. After the beginning of immunotherapy (within 30 days after), 8% received a corticoid, 6% an antibiotic and 2% an antifungal. Response to treatment, Progression Free Survival and Overall Survival (PFS and OS) in correlation with the use or not of these drugs for Bretagne and PL areas would be presented at the meeting. Conclusions: The good use of immunotherapy was crucial to optimize the response rate and to increase OS. Use of anti-infectious and corticosteroids was usual in routine. Antibiotics were found to be prescribed in 20% of the patients receiving immunotherapy. Results about their impact in term of response, PFS and OS would be shown at the meeting. Legal entity responsible for the study: Cancer Observatoire BPL, OMEDIT B and PL. 
